Focus Partners Advisor Solutions LLC has significantly increased its investment in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by an impressive 533% during the third quarter of 2023....
Alnylam Pharmaceuticals has announced the initiation of a Phase 3 cardiovascular outcomes trial for its hypertension therapy, zilebesiran, later this year. This decision comes despite recent...
